Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galderma Group AGXSWX:GALD +1.53%14 EV-to-EBIT is 64.36 as of Jul. 20, 2026, which is 29% above its 10-year median of 49.85. GuruFocus rates XSWX:GALD with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 689 Drug Manufacturers companies, Galderma Group AG ranks worse than 89.55% on this metric.
Galderma Group AG (XSWX:GALD) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Galderma Group AG's Enterprise Value for the quarter that ended in Dec. 2025 was CHF39,597 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galderma Group AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF654 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG EV-to-EBIT Related Terms
Galderma Group AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's EV-to-EBIT falls into.
Galderma Group AG's current Enterprise Value is CHF42,061 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galderma Group AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF654 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (XSWX:GALD) has a EV-to-EBIT of 64.36 as of Jul. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Galderma Group AG and its competitors. This is 29% above median its historical median of 49.85. Over the past decade, Galderma Group AG's EV-to-EBIT has ranged from 33.93 to 69.17. According to the industry distribution chart, Galderma Group AG ranks #617 out of 689 companies in the Drug Manufacturers industry, placing it in the top 89.6%.
Is Galderma Group AG's EV-to-EBIT too high?
Galderma Group AG's current EV-to-EBIT of 64.36 is 29% above median its 10-year median of 49.85. Over the past 10 years, this metric has ranged from a low of 33.93 to a high of 69.17. The Drug Manufacturers industry median EV-to-EBIT is 16.00. Galderma Group AG's value of 64.36 is 302.3% above this industry median. Based on the distribution chart, Galderma Group AG ranks #617 out of 689 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Galderma Group AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #617 out of 689 companies for EV-to-EBIT. This places Galderma Group AG in the lower half of its industry. The industry median EV-to-EBIT is 16.00. Galderma Group AG's value of 64.36 is 302.3% above this benchmark. Historically, Galderma Group AG's own EV-to-EBIT has ranged from 33.93 to 69.17 over the past decade. While the company's 10-year median is 49.85 vs. the industry median of 16.00, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.00, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current EV-to-EBIT of 64.36 is 302.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current EV-to-EBIT is 64.36, which is 29% above median its own 10-year median of 49.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current EV-to-EBIT of 64.36. The current EV-to-EBIT is 64.36, which is 29% above median its 10-year median of 49.85 and 302.3% above the Drug Manufacturers industry median of 16.00. Galderma Group AG's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current EV-to-EBIT is 64.36 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
14GF Score
Get the complete analysis for XSWX:GALD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 
